Generic Name and Formulations:
Ticarcillin disodium 3g; IM or IV inj; sodium content 5.2–6.5mEq/g.
Various generic manufacturers
Indications for Ticarcillin:
Susceptible bacterial septicemia, respiratory or urinary tract, skin and soft tissue, gynecologic, intraabdominal infections.
UTI: 1g IM or IV every 6 hours. Systemic: 150–300mg/kg/day IV in divided doses every 4–6 hours. Max IM 2g per inj. In more severe infections use higher doses by IV route.
Neonates <2kg: 75mg/kg every 12 hours until 7 days old, then 75mg/kg every 8 hours. >2kg: 75mg/kg every 8 hours until 7 days old, then 100mg/kg every 8 hours. Others <40kg: UTI: 50–100mg/kg/day IM or IV in divided doses every 6–8 hours. Systemic: 150–300mg/kg/day IV in divided doses every 4–6 hours. >40kg: as adult.
Cephalosporin, imipenem, or other allergy: not recommended. Renal impairment, reduce dose (see literature) and monitor for bleeding disorders. Heart disease. Sodium restricted diets. Monitor serum electrolytes (esp. potassium) and renal, hepatic, hematopoietic function during prolonged therapy. Pregnancy.
Potentiated by probenecid.
Inj site reactions, rash, pruritus, drug fever, GI upset, blood dyscrasias, hemorrhage, hypokalemia, anaphylaxis, CNS stimulation, elevated liver enzymes.
Formerly known under the brand name Ticar.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking